Baxter submits BLA for OBI-1 in acquired hemophilia A, supplemental filing for Rixubis
This article was originally published in Scrip
Executive Summary
Baxter International submitted a biologics license application (BLA) to the US FDA for OBI-1 (recombinant porcine factor VIII) in the treatment of acquired hemophilia A less than a year after the company acquired the product candidate from Inspiration Pharmaceuticals.